Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and depletes pathological immune cells.
Location: United States, California, South San Francisco
Total raised: $84M
Investors 3
| Date | Name | Website |
| 18.02.2022 | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| 23.03.2022 | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.02.2022 | Series B | $84M | - |
Mentions in press and media 3
| Date | Title | Description |
| 17.02.2022 | Electra Therapeutics Raises $84M in Series B Financing | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company, raised $84M in Series B funding. The round was led by Westlake Village BioPartners and OrbiMed with participation from Redmile Group, Cormorant Asse... |
| 16.02.2022 | Electra Therapeutics Announces $84M Series B | SOUTH SAN FRANCISCO, CA, Electra Therapeutics, a biotechnology company, raised a $84M Series B financing co-led by Westlake Village BioPartners and OrbiMed. >> Click here for more funding data on Electra Therapeutics >> To e... |
| 13.02.2022 | Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancer | - |